Evidence map›Paper›PMID 41406948›Full record

ArticleCell reports. Medicine2025

Plasma growth-associated protein 43 correlates with synaptic loss in Alzheimer's disease.

Guoyu Lan, Binyin Li, Mengjie Wang, Aatmika Barve, Morvane Colin, Luc Buée, Laihong Zhang, Mingxing Jiang, Jie Yang, Anqi Li and 26 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Hyperprogressive disease in carcinoma induced by immune checkpoint inhibitor therapy: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Guoyu LanInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Binyin LiDepartment of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Mengjie WangDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai 200040, China.
Aatmika BarveCentre for Psychiatric Neurosciences (CNP), Lausanne University Hospital (CHUV) - University of Lausanne (UNIL), 1015 Lausanne, Switzerland.
Morvane ColinUniversity Lille, Inserm, CHU-Lille, LilNCog-Lille Neuroscience & Cognition, 59000 Lille, France.
Luc BuéeUniversity Lille, Inserm, CHU-Lille, LilNCog-Lille Neuroscience & Cognition, 59000 Lille, France.
Laihong ZhangInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China; School of Biology and Biological Engineering, South China University of Technology, Guangzhou 510641, China.
Mingxing JiangShenzhen Medical Academy of Research and Translation, Shenzhen 518132, China; Westlake University, Hangzhou 310024, China.
Jie YangInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China; Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Anqi LiInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China; Division of Life Science, The Hong Kong University of Science and Technology, Hong Kong 999077, China.
Zhengbo HeInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China; School of Life Science and Technology, Harbin Institute of Technology, Harbin 150001, China.
Xin ZhouInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China; School of Biomedical Engineering, Hainan University, Haikou 570228, China.
Yalin ZhuInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China; Division of Life Science, The Hong Kong University of Science and Technology, Hong Kong 999077, China.
Yue CaiInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Pan SunInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Lin LiuInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Jieyin LiInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Linting ChenInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Lili FangInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Yiying WangInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Mingxu LiDepartment of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Xuhui ChenDepartment of Neurology, Peking University Shenzhen Hospital, Shenzhen 518132, China.
Dai ShiNeurology Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, China.
Chenghui YeNeurology Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, China.
Xiang FanDepartment of Medical Imaging, Peking University Shenzhen Hospital, Shenzhen 518132, China.
Qingyong WangDepartment of Neurology, Shenzhen Guangming District People's Hospital, Shenzhen 518132, China.
Liemin ZhouNeurology Medicine Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518000, China.
Zhen LiuInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Ying HanInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China; Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; School of Biomedical Engineering, Hainan University, Haikou 570228, China.
Lu WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
Guanxun ChengDepartment of Medical Imaging, Peking University Shenzhen Hospital, Shenzhen 518132, China.
Yihui GuanDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai 200040, China.
Ruiqing NiInstitute for Regenerative Medicine, University of Zurich, Zurich, Switzerland; Institute for Biomedical Engineering, University of Zurich & ETH Zurich, Zurich, Switzerland.
Kevin RichetinCentre for Psychiatric Neurosciences (CNP), Lausanne University Hospital (CHUV) - University of Lausanne (UNIL), 1015 Lausanne, Switzerland; Leenaards Memory Centre, Lausanne University Hospital (CHUV) - University of Lausanne (UNIL), 1011 Lausanne, Switzerland; Department of Clinical Neuroscience (DNC), Laboratory of Neurotherapies and Neuromodulation, Lausanne University Hospital (CHUV) and University of Lausanne, 1011 Lausanne, Switzerland. Electronic address: kevin.richetin@chuv.ch.
Fang XieDepartment of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai 200040, China. Electronic address: fangxie@fudan.edu.cn.
Tengfei GuoInstitute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China; Shenzhen Medical Academy of Research and Translation, Shenzhen 518132, China; Institute of Biomedical Engineering, Peking University Shenzhen Graduate School, Peking University, Shenzhen 518132, China. Electronic address: tengfei.guo@szbl.ac.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synaptic loss is a hallmark of Alzheimer's disease (AD) but lacks robust blood-based biomarkers. We investigate growth-associated protein 43 (GAP-43), previously identified as a synaptic candidate in the cerebrospinal fluid (CSF). Postmortem proteomic profiling of brain-derived extracellular vesicles (n = 21) highlights GAP-43 as a central hub within synaptic protein networks co-depleted in AD and closely linked with proteins enriched in immune-, metabolic-, and synaptic-related modules. In two well-characterized Chinese AD cohorts (n = 785), we measure plasma GAP-43, including subgroups with CSF biomarkers (n = 72), SV2A-PET (positron emission tomography) (n = 85), tau-PET (n = 280), and magnetic resonance imaging (MRI) (n = 595). Plasma GAP-43 correlates with CSF GAP-43, neurofilament light, and both baseline and longitudinal synaptic PET. Elevated plasma GAP-43 is associated with greater tau aggregation, faster brain atrophy, and accelerated cognitive decline, particularly among cognitively unimpaired individuals. These findings support plasma GAP-43 as a promising biomarker of early synaptic degeneration and a potential tool for identifying individuals at risk of AD progression.

Indexed as

Alzheimer DiseaseGAP-43 ProteinSynapsesAgedAged, 80 and overBiomarkersBrainCognitive DysfunctionFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedPositron-Emission Tomographytau ProteinsBiomarkersGAP-43 Proteintau ProteinsAlzheimer’s diseaseblood biomarkersextracellular vesiclesGAP-43neuropathologysynaptic loss

Identifiers

PMID41406948
PMCPMC12765837

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.